ClinicalTrials.gg
TerminatedNCT05243524AVALONUpdated Sep 13, 2023

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

A Phase 2 interventional study of Maveropepimut-S and Cyclophosphamide 50mg in Platinum-resistant Epithelial Ovarian Cancer, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.). Terminated at 6 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Closure of IMV operations

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cyclophosphamide in Carcinoma, Ovarian Epithelial — 1 open to participants now, 2 under way, none of them phase 3. Cyclophosphamide · Carcinoma, Ovarian Epithelial.

Enrollment
8th of 13
16 · median 20
Started
2022
the only one that year
Phase 2
3 of 15
none open now
Registered
14th of 15
by date
Lead sponsor
3 of 15
ImmunoVaccine Technologies, Inc. (IMV Inc.)

Among the 15 studies testing cyclophosphamide in Carcinoma, Ovarian Epithelial, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 2, and was the 14th registered.

Carcinoma, Ovarian Epithelial

798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.

Browse Carcinoma, Ovarian Epithelial studies →

Open to participants now

1 of the 15 studies testing cyclophosphamide in Carcinoma, Ovarian Epithelial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cyclophosphamide in Carcinoma, Ovarian Epithelial, or all of them as a file.
02

Study summary

Phase 2, single arm, study to assess the efficacy and safety of maveropepimut-S (MVP-S) and low-dose cyclophosphamide (CPA) in subjects with recurrent, platinum resistant ovarian cancer.

Read the detailed description

A Simon two-stage statistical design to assess MVP-S in combination with low dose CPA in platinum-resistant epithelial ovarian cancer patients who have received no greater than 4 previous lines of anti-cancer therapy.

MVP-S, previously called DPX-Survivac, was recently evaluated in a small Phase 2 single arm study of ovarian cancer patients known as DeCidE1 (NCT02785250).

03

Conditions studied

  • Platinum-resistant Epithelial Ovarian Cancer

Keywords

  • T cell education
  • DPX-Survivac
  • Immunotherapy
  • Platinum-resistant (PROC)
  • High grade serous (HGSOC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, diagnosed high-grade serous
  • Platinum-resistant disease (relapsing within 3-6 months after completion of initial platinum-based treatment). Patients progressing at any time on or after ≥ 2nd platinum-based therapy are eligible.
  • Received ≤ 4 prior lines of anti-cancer therapy for ovarian cancer, including at least one platinum-based therapy
  • Evidence of progressive disease
  • ( v1.1) with at least one non-target lesion accessible by image-guided . No single lesion may be larger than 4 cm in diameter.
  • Completed pre-treatment tumor biopsy and willing to undergo on-treatment tumor biopsy
  • 0-1
  • Live expectancy ≥ 6 months
  • Meet protocol-specified laboratory requirements

Key Exclusion Criteria:

  • Concurrent chemotherapy drugs, anti-cancer therapy or anti-neoplastic hormonal therapy, or radiotherapy
  • Prior receipt of survivin-based vaccines/therapy, , IDO inhibitor, or cell-based therapy
  • Non-epithelial tumor origin of the ovary, fallopian tube, or peritoneum
  • Clinical ascites
  • Concurrent second other than basal or squamous cell skin cancer, cervical carcinoma in situ, or Stage I or II caner in complete remission
  • GI condition that might limit absorption of oral agents
  • Recent history of thyroiditis
  • History of disease requiring treatment within the last two years (except paraneoplastic syndrome, vitiligo, or diabetes)
  • History of bowel obstruction related to the disease
  • Presence of a serious acute infection or chronic infection
  • Uncontrolled concurrent illness or history of significant cardiac or pulmonary disfunction
  • Myocardial infarction or cerebrovascular event within past 6 months
  • Known central nervous system (CNS) or ()
  • illness or major surgery within past 28 days or anticipated need for major surgery during study treatment
  • Ongoing treatment with therapy or other
  • Receipt of
  • Edema or lymphedema in the lower limbs > grade 2
  • Acute or chronic skin and/or microvascular disorders
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    MVP-S + CPA

    All subjects will receive two doses of maveropepimut-S (q3w) followed by up to six doses (q8w) plus low-dose cyclophosphamide on a repeating cycle of one week on/one week off.

    Other: Maveropepimut-S · Drug: Cyclophosphamide 50mg

Interventions

  • OtherMaveropepimut-S

    SC injection on days 7, 28, then q8w

    Also known as: MVP-S, DPX-Survivac

  • PO BID, one week on, one week off

    Also known as: CPA, Procytox, Cytoxan

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    per RECIST v1.1 criteria

    Time frame: up to 13 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    per iRECIST criteria

    Time frame: up to 13 months

  2. Duration of Response (DOR)

    Time frame: up to 23 months

  3. Disease Control Rate (DCR)

    Time frame: up to 13 months

  4. Time to Progression (TTP)

    Time frame: up to 23 months

  5. Progression Free Survival (PFS)

    Time frame: up to 23 months

  6. Progression Free Survival (6m PFS)

    Time frame: at 6 months

  7. Overall Survival (OS)

    Time frame: up to 23 months

  8. CA-125 Response

    monthly measurements

    Time frame: up to 13 months

  9. Frequency of adverse events

    graded using NCI CTCAE v5.0

    Time frame: up to 13 months

Other outcomes

  1. Cell mediated immune response

    analysis of PBMC/plasma samples

    Time frame: up to 13 months

  2. Changes in Tumor Micro-environment (TME)

    analysis of paired biopsies

    Time frame: up to 2 months

07

Study locations

6 sites
  • Stanford Health Care
    Palo Alto, California 94305, United States
  • Ocala Oncology
    Ocala, Florida 34474, United States
  • NYU Langone Hospital-Long Island
    Mineola, New York 11501, United States
  • NYU Langone: Laura and Isaac Perlmutter Cancer Center
    New York, New York 10016, United States
  • CHUM - Centre hospitalier de l'Université de Montréal
    Montréal, Quebec H2X 0A9, Canada
  • PanOncology Trials
    San Juan, 00935, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Jul 2023, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Feb 17, 2022
StartActual
Aug 5, 2022
Primary completionActual
Jul 24, 2023
CompletionActual
Aug 31, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05243524
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Aug 5, 2022
Primary completion
Jul 24, 2023
Completion
Aug 31, 2023
Last update
Sep 13, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclophosphamide

Start the discussion